US4920115A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of lowering LDL cholesterol in blood
Assignee: Virginia Commonwealth University
•
Filing: 1988-12-28
•
Granted: 1990-04-24
•
Expires: 2008-12-28
Abstract
Abstract Therapeutic amounts of DHEA are administered to human patients for the treatment and prevention of such disorders as atherosclerosis, angina, diabetes, obesity and congestive heart failure. Administering therapeutic quantities of DHEA to human patients has been found to reduce body fat mass and increase muscle mass, lower serum LDL cholesterol levels, lower serum apoB levels, and not affect tissue sensitivity to insulin.
Inventors
- 👤 John E. Nestler
- 👤 Cornelius O. Barlascini
- 👤 John N. Clore
- 👤 William G. Blackard
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 20:20
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/565
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
36 words
A method of lowering low density lipoprotein cholesterol concentrations in human beings, comprising a step of administering a therapeutic dose of dehydroepiandrosterone to a patient to lower said low density lipoprotein cholesterol concentration in said patient.
Claim 2
Independent Claim
36 words
A method of lowering low density lipoprotein cholesterol concentrations in human beings, comprising a step of administering a therapeutic dose of dehydroepiandrosterone to a patient to lower said low density lipoprotein cholesterol concentration in said patient.
Claim 3
Dependent Claim
25 words
A method as recited in claim 1 wherein said therapeutic dose comprises a daily amount of said dehydroepiandrosterone ranging between 100 milligrams and 1800 milligrams.
Claim 4
Dependent Claim
15 words
A method as recited in claim 2 wherein said daily amount is approximately 1600 milligrams.
Claim 5
Dependent Claim
26 words
A method as recited in claim 2 wherein said daily amount is ingested orally in capsule form wherein said dehydroepiandrosterone is held in an inert binder.
Claim 6
Independent Claim
32 words
A method of lowering apolipoprotein B concentrations in human beings, comprising a step of administering a therapeutic dose of dehydroepiandrosterone to a patient to lower said apolipoprotein B concentration in said patient.
Claim 7
Independent Claim
32 words
A method of lowering apolipoprotein B concentrations in human beings, comprising a step of administering a therapeutic dose of dehydroepiandrosterone to a patient to lower said apolipoprotein B concentration in said patient.
Claim 8
Dependent Claim
25 words
A method as recited in claim 5 wherein said therapeutic dose comprises a daily amount of said dehydroepiandrosterone ranging between 100 milligrams and 1800 milligrams.
Claim 9
Dependent Claim
15 words
A method as recited in claim 6 wherein said daily amount is approximately 1600 milligrams.
Claim 10
Dependent Claim
26 words
A method as recited in claim 6 wherein said daily amount is ingested orally in capsule form wherein said dehydroepiandrosterone is held in an inert binder.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-23 | 1993-10-23 | 1994-04-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-23 | 1997-10-23 | 1998-04-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-23 | 2001-10-23 | 2002-04-24 | $7700.00 | Window Closed / Lapsed |